Feedback
Settings

Settings

Goto Application

1. WO2022165255 - GUT MICROBIOME AS A PREDICTIVE BIOMARKER OF OUTCOMES FOR CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

Submit observation
PermaLink
Publication Number WO/2022/165255
Publication Date 04.08.2022
International Application No. PCT/US2022/014420
International Filing Date 28.01.2022
IPC
A61K 35/74 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
C12Q 1/6886 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 1/689 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
CPC
A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/5443
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
5443IL-15
C07K 14/7155
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
7155for interleukins [IL]
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
Applicants
  • BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US]/[US]
Inventors
  • SAINI, Neeraji
  • CHANG, Chia-Chi
  • JENQ, Robert R.
  • NEELAPU, Sattva S.
Agents
  • SISTRUNK, Melissa L.
Priority Data
63/143,66529.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) GUT MICROBIOME AS A PREDICTIVE BIOMARKER OF OUTCOMES FOR CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
(FR) MICROBIOME INTESTINAL UTILISÉ EN TANT QUE BIOMARQUEUR PRÉDICTIF DE RÉSULTATS POUR UNE THÉRAPIE PAR LYMPHOCYTES T DE RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE
front page image
Abstract
(EN) The present disclosure concerns methods and compositions related to adoptive cell therapy and its efficacy related to the gut microbiome. In specific cases, it may be determined for an individual whether or not a chimeric antigen receptor (CAR) T-cell therapy will be effective for an individual based on their gut microbiome. An individual may be provided a composition comprising one or more particular microbe compositions based on analysis of the gut microbiome of the individual and prior to administration of CAR T-cell therapy, in specific embodiments.
(FR) La présente invention concerne des méthodes et des compositions associées à la thérapie cellulaire adoptive et son efficacité liée au microbiome intestinal. Dans des cas spécifiques, il peut être déterminé pour un individu si une thérapie par lymphocytes T du récepteur antigénique chimérique (CAR) sera efficace pour un individu sur la base de son microbiome intestinal. Un individu peut se voir administrer une composition comprenant une ou plusieurs compositions microbiennes particulières sur la base d'une analyse du microbiome intestinal de l'individu et avant administration d'une thérapie par lymphocytes T CAR, dans des modes de réalisation spécifiques.
Latest bibliographic data on file with the International Bureau
# -